Therapeutic options for metastatic breast cancer
Abstract
Metastatic breast cancer (MBC) remains an incurable disease despite ongoing therapeutic advances. Recently there has been progress extending the range of available cytotoxic chemotherapy drugs and optimizing their scheduling. In addition, a greater understanding of tumor biology has led to the development of a number of targeted therapies. Several of these newer agents, such as trastuzumab, lapatinib and bevacizumab, have demonstrated activity in combination with chemotherapy and have improved the prognosis of patients with MBC. We hope that further progress elucidating the pathophysiology and biology of MBC will continue to lead to corresponding advances in treatment.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Clinically and biologically, metastasis is intricately linked with resistance to chemotherapy.
“Clinically as well as biologically, metastasis is intricately linked with resistance to chemotherapy (Hu et al., 2009; Morris et al., 2009).”
From A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis (2012) · cites this paper as Morris et al., 2009
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · see citing works
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J. K., Lindquist, D. L., Chan, S. Y. T., Romieu, C. G., Pieńkowski, T., Jagiełło-Gruszfeld, A., Crown, J. P., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,426 · see citing works
Vogel, C. L., Cobleigh, M., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.719 · Cited by 3,240 · see citing works
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K. D., Wang, M., Gralow, J. R., Dickler, M. N., Cobleigh, M., Perez, E. A., Shenkier, T. N., Cella, D. F., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,077 · see citing works
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767 · see citing works
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,592 · see citing works
Self-citationStewart, B. W., & Kleihues, P. (2003) · Cited by 2,389 · see citing works
Gradishar, W. J., Tjulandin, S., Davidson, N. G. P., Shaw, H., Desai, N. P., Bhar, P., Hawkins, M., & O’Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,159 · see citing works
Marty, M. E., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S. Y. T., Grimes, D., Antón, A., Lluch, A. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,588 · see citing works
Baselga, J. M., Tripathy, D., Mendelsohn, J. M., Baughman, S. A., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J. L., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,382 · see citing works
Self-citationMiller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M., Marcom, P. K., Fehrenbacher, L., Dickler, M. N., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,303 · see citing works
O’Shaughnessy, J., Miles, D., Vukelja, S. J., Moiseyenko, V. M., Ayoub, J.-P., Cervantes, G., Fumoleau, P., Jones, S. E., Lui, W., Mauriac, L., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.002 · Cited by 1,078 · see citing works
Nabholtz, J., Buzdar, A. U., Pollak, M., Harwin, W. N., Burton, G., Mangalik, A., Steinberg, M., Webster, A., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3758 · Cited by 989 · see citing works
Action of 2',2'-difluorodeoxycytidine on DNA synthesis.
Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B., & Plunkett, W. K. (1991) · PubMed · Cited by 876 · see citing works
Bonneterre, J. M., Thurlimann, B. J. K., Robertson, J. F. R., Krzakowski, M. J., Mauriac, L., Koralewski, P., Vergote, I. B., Webster, A., Steinberg, M., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3748 · Cited by 839 · see citing works
THE IMPACT OF NATIONAL CANCER ACT
Holmes, F. A., Walters, R. S., Theriault, R. L., Buzdar, A. U., Frye, D. K., Hortobágyi, G. N., Forman, A. D., Newton, L. K., & Raber, M. N. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797 · Cited by 796 · see citing works
Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer
Blum, J. L., Jones, S. E., Buzdar, A. U., LoRusso, P. M., Kuter, I., Vogel, C. L., Osterwalder, B., Burger, H.-U., Brown, C., & Griffin, T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.485 · Cited by 780 · see citing works
Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer
Holmes, F. A., Walters, R. S., Theriault, R. L., Buzdar, A. U., Frye, D., Hortobágyi, G. N., Forman, A. D., Newton, L. K., & Raber, M. N. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797-a · Cited by 744 · see citing works
Mouridsen, H. T., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jaenicke, F., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.194 · Cited by 741 · see citing works
Sledge, G. W., Neuberg, D. S., Bernardo, P., Ingle, J. N., Martino, S., Rowinsky, E. K., & Wood, W. C. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.013 · Cited by 708 · see citing works
A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474
Cole, M. P., Jones, C. T. A., & Todd, I. (1971) · British Journal of Cancer · doi:10.1038/bjc.1971.33 · Cited by 701 · see citing works
Howell, A., Robertson, J. F. R., Albano, J., Aschermannová, A., Mauriac, L., Kleeberg, U. R., Vergote, I. B., Erikstein, B., Webster, A., & Morris, C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.057 · Cited by 672 · see citing works
Osborne, C. K., Pippen, J., Jones, S. E., Parker, L. M., Ellis, M. J., Come, S., Gertler, S. Z., May, J., Burton, G., Dimery, I. W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.058 · Cited by 641 · see citing works
Seidman, A. D., Berry, D. A., Cirrincione, C., Harris, L. N., Muss, H. B., Marcom, P. K., Gipson, G., Burstein, H. J., Lake, D. E., Shapiro, C. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6699 · Cited by 596 · see citing works
Self-citationRandomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
Jones, S. E., Erban, J. K., Overmoyer, B. A., Budd, G. T., Hutchins, L. F., Lower, E. E., Laufman, L. R., Sundaram, S., Urba, W. J., Pritchard, K. I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.027 · Cited by 547 · see citing works
Chia, S., Gradishar, W. J., Mauriac, L., Bines, J., Amant, F. C., Federico, M. H. H., Fein, L. E., Romieu, G., Buzdar, A. U., Robertson, J. F. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5822 · Cited by 514 · see citing works
Thomas, E. S., Gómez, H., Li, R. K., Chung, H. C., Fein, L. E., Chan, V. F., Jassem, J., Pivot, X. B., Klimovsky, J., Mendoza, F., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6557 · Cited by 489 · see citing works
Lee, F. Y., Borzilleri, R. M., Fairchild, C. R., Kim, S., Long, B. H., Raventós-Suárez, C., Vite, G. D., Rose, W. C., & Kramer, R. A. (2001) · PubMed · Cited by 453 · see citing works
Thomas, E. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5019 · Cited by 429 · see citing works
Albain, K. S., Nag, S. M., Calderillo-Ruiz, G., Jordaan, J. P., Llombart‐Cussac, A., Pluzanska, A., Rolski, J., Melemed, A. S., Reyes-Vidal, J. M., Sekhon, J. S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9362 · Cited by 425 · see citing works
Howell, A., Robertson, J. F. R., Abram, P., Lichinitser, M., Elledge, R. M., Bajetta, E., Watanabe, T., Morris, C. Q., Webster, A., Dimery, I. W., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.112 · Cited by 422 · see citing works
Perez, E. A., Lerzo, G. L., Pivot, X. B., Thomas, E. S., Vahdat, L. T., Bosserman, L. D., Viens, P., Cai, C., Mullaney, B. P., Peck, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3849 · Cited by 393 · see citing works
Seidman, A. D., Hudis, C. A., Albanell, J., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3353 · Cited by 382 · see citing works
Self-citationBurstein, H. J., Harris, L. N., Marcom, P. K., Lambert-Falls, R., Havlin, K. A., Overmoyer, B. A., Friedlander, R. J., Gargiulo, J., Strenger, R., Vogel, C. L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.018 · Cited by 342 · see citing works
Advanced breast cancer: a phase II trial with gemcitabine.
Carmichael, J., Possinger, K., Phillip, P., et al. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2731 · Cited by 339 · see citing works
Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy.
Fumoleau, P., Delgado, F.-M., Delozier, T., et al. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.7.1245 · Cited by 327 · see citing works
Ravdin, P., Burris, H. A., Cook, G., et al. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.12.2879 · Cited by 318 · see citing works
Fumoleau, P., Largillier, R., Clippe, C., Dieras, V. C., Orfeuvre, H., Lesimple, T., Culine, S., Audhuy, B., Serin, D., Curé, H., et al. (2003) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.007 · Cited by 304 · see citing works
O’Shaughnessy, J., Blum, J. L., Moiseyenko, V. M., Jones, S. E., Miles, D., Bell, D., Rosso, R., Mauriac, L., Osterwalder, B., Burger, H. U., et al. (2001) · Annals of Oncology · doi:10.1023/a:1012281104865 · Cited by 302 · see citing works
Nyman, D. W., Campbell, K. J., Hersh, E. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.6148 · Cited by 286 · see citing works
Winer, E. P., Berry, D. A., Woolf, S., Duggan, D. B., Kornblith, A. B., Harris, L. N., Michaelson, R. A., Kirshner, J., Fleming, G. F., Perry, M. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.048 · Cited by 270 · see citing works
Self-citationDocetaxel Administered on a Weekly Basis for Metastatic Breast Cancer
Burstein, H. J., Manola, J. B., Younger, J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1212 · Cited by 263 · see citing works
Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines
Haller, D. G., Cassidy, J., Clarke, S. J., Cunningham, D., Cutsem, E. V., Hoff, P. M., Rothenberg, M. L., Saltz, L. B., Schmoll, H., Allegra, C. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2090 · Cited by 252 · see citing works
Multicenter Phase II Trial of Weekly Paclitaxel in Women With Metastatic Breast Cancer
Perez, E. A., Vogel, C. L., Irwin, D. H., Kirshner, J. J., & Patel, R. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.22.4216 · Cited by 248 · see citing works
Klijn, J. G. M. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.11.903 · Cited by 247 · see citing works
Reichardt, P., von Minckwitz, G., Thuss-Patience, P. C., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg346 · Cited by 238 · see citing works
Reichman, B. S., Seidman, A. D., Crown, J. P., et al. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1943 · Cited by 237 · see citing works
Hayes, D. F., Zyl, J. A. V., Hacking, A., et al. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.10.2556 · Cited by 220 · see citing works
Miles, D., Chan, A., Romieu, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.lba1011 · Cited by 214 · see citing works
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
Valero, V., Jones, S. E., Hoff, D. D. V., Booser, D. J., Mennel, R. G., Ravdin, P. M., Holmes, F. A., Rahman, Z., Schottstaedt, M. W., Erban, J. K., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3362 · Cited by 212 · see citing works
Platinum-based chemotherapy in metastatic breast cancer: current status
Decatris, M. P., Sundar, S., & O'Byrne, K. J. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00139-7 · Cited by 212 · see citing works
Bajetta, E., Procopio, G., Celio, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.167 · Cited by 208 · see citing works
Seidman, A. D., Tiersten, A., Hudis, C. A., et al. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.10.2575 · Cited by 204 · see citing works
Self-citationSeidman, A. D., Reichman, B. S., Crown, J. P., Yao, T., Currie, V. E., Hakes, T. B., Hudis, C. A., Gilewski, T., Baselga, J. M., & Forsythe, P. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.5.1152 · Cited by 204 · see citing works
Self-citationVinorelbine as first-line chemotherapy for metastatic breast carcinoma.
Romero, A., Rabinovich, M. G., Vallejo, C. T., et al. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.2.336 · Cited by 189 · see citing works
Martín, M., Ruı́z, A., Muñoz-Mateu, M., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70041-4 · Cited by 187 · see citing works
The Biology and Medicinal Chemistry of Epothilones
Wartmann, M., & Altmann, K. (2005) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011023354489 · Cited by 182 · see citing works
Talbot, D. C., Moiseyenko, V. M., Belle, S. V., O'Reilly, S. M., Alba, E., Ackland, S. P., Eisenberg, P. D., Melnychuk, D., Pieńkowski, T., Burger, H.-U., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600261 · Cited by 179 · see citing works
Ingle, J. N., Krook, J. E., Green, S. J., et al. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.2.178 · Cited by 174 · see citing works
Gasparini, G. M., Caffo, O., Barni, S., et al. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.10.2094 · Cited by 161 · see citing works
Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial
Blackstein, M. E., Vogel, C. L., Ambinder, R. M., et al. (2002) · Oncology · doi:10.1159/000048240 · Cited by 161 · see citing works
Buchanan, R. B., Blamey, R. W., Durrant, K. R., et al. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.9.1326 · Cited by 160 · see citing works
O’Shaughnessy, J., Blackwell, K. L., Burstein, H. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.1015 · Cited by 157 · see citing works
Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer
Degardin, M., Bonneterre, J. M., Hecquet, B., et al. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058873 · Cited by 147 · see citing works
Boccardo, F., RUBAGOTTI, A., Perrotta, A., et al. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058837 · Cited by 136 · see citing works
Possinger, K., Kaufmann, M., Coleman, R., et al. (1999) · Anti-Cancer Drugs · doi:10.1097/00001813-199902000-00003 · Cited by 131 · see citing works
Cardiac profiles of liposomal anthracyclines
Theodoulou, M., & Hudis, C. A. (2004) · Cancer · doi:10.1002/cncr.20207 · Cited by 130 · see citing works
Self-citationTamoxifen in premenopausal patients with metastatic breast cancer: a review.
Sunderland, M. C., & Osborne, C. K. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.7.1283 · Cited by 123 · see citing works
Risk of ovarian carcinoma and consumption of vitamins A, C, and E and specific carotenoids
Fairfield, K. M., Hankinson, S. E., ROSNER, B. A., Hunter, D. J., Colditz, G. A., & Willett, W. C. (2001) · Cancer · doi:10.1002/1097-0142(20011101)92:9 · Cited by 121 · see citing works
O’Shaughnessy, J., Vukelja, S., Marsland, T., Kimmel, G. T., Ratnam, S., & Pippen, J. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.019 · Cited by 114 · see citing works
Paridaens, R., Therasse, P., Dirix, L. Y., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.515 · Cited by 109 · see citing works
Jonat, W., Kaufmann, M., Blamey, R. W., et al. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(94)00415-2 · Cited by 105 · see citing works
Pyrhönen, S. O., Valavaara, R., Modig, H. G., et al. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.375 · Cited by 98 · see citing works
Feher, O., Vodvarka, P., Jassem, J., Morack, G., Advani, S. H., Khoo, K. S., Doval, D. C., Ermisch, S., Roychowdhury, D., Miller, M. A., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi181 · Cited by 92 · see citing works
Angiogenesis in pancreatic carcinoma
Fujioka, S., Yoshida, K., Yanagisawa, S., Kawakami, M., Aoki, T., & Yamazaki, Y. (2001) · Cancer · doi:10.1002/1097-0142(20011001)92:7 · Cited by 90 · see citing works
Papaldo, P., Fabi, A., Ferretti, G., Mottolese, M., Cianciulli, A. M., Cocco, B. D., Pino, M. S., Carlini, P., Cosimo, S. D., Sacchi, I., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj110 · Cited by 82 · see citing works
von Minckwitz, G., Zielinski, C., Maarteense, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.1025 · Cited by 80 · see citing works
Traina, T. A., Theodoulou, M., Feigin, K., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8388 · Cited by 72 · see citing works
Muss, H. B., Case, L. D., Atkins, J., Bearden, J. D., Cooper, M. R., Cruz, J. M., Jackson, D. V., O’Rourke, M. A., Pavy, M. D., & Powell, B. L. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1630 · Cited by 70 · see citing works
Johnston, S. R. D., Pegram, M. D., Press, M. F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-46 · Cited by 66 · see citing works
ten Tije, A. J., Smorenburg, C. H., Seynaeve, C., et al. (2003) · European Journal of Cancer · doi:10.1016/j.ejca.2003.08.013 · Cited by 66 · see citing works
Bartsch, R., Wenzel, C., Gampenrieder, S. P., et al. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0682-1 · Cited by 45 · see citing works
Gennatas, C., Michalaki, V., Carvounis, E. E., et al. (2006) · Tumori Journal · doi:10.1177/030089160609200103 · Cited by 43 · see citing works
Lombardi, D., Crivellari, D., Scuderi, C., et al. (2004) · Tumori Journal · doi:10.1177/030089160409000304 · Cited by 37 · see citing works
Chin, Y. S., Beresford, M. J., Ravichandran, D., et al. (2007) · The Breast · doi:10.1016/j.breast.2007.02.002 · Cited by 29 · see citing works
Miles, B. J., & Eigl, B. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5077 · Cited by 28 · see citing works
Sato, K. (2003) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyg075 · Cited by 27 · see citing works
Bayo-Calero, J. L., Mayordomo, J. I., Sánchez‐Rovira, P., et al. (2008) · Clinical Breast Cancer · doi:10.3816/cbc.2008.n.030 · Cited by 23 · see citing works
Weekly Paclitaxel in Metastatic Breast Cancer Patients: A Phase II Study
Gori, S., Mosconi, A. M., Basurto, C., et al. (2002) · Tumori Journal · doi:10.1177/030089160208800607 · Cited by 22 · see citing works
Weekly Low Dose Epirubicin in Elderly Cancer Patients
Nicolella, D., Grimaldi, G., Colantuoni, G., et al. (1996) · Tumori Journal · doi:10.1177/030089169608200414 · Cited by 20 · see citing works
Archer, C. D., Lowdell, C. P., Sinnett, H. D., et al. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10113-7 · Cited by 19 · see citing works
Schaller, G., Bangemann, N., Weber, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.717 · Cited by 19 · see citing works
Phase II and III clinical trials of toremifene for metastatic breast cancer.
Vogel, C. L. (1998) · PubMed · Cited by 15 · see citing works
Tokudome, N., Ito, Y., Hatake, K., et al. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328302eb15 · Cited by 10 · see citing works
Metastatic breast cancer (MBC): FDA approval overview
Cortazar, P., Johnson, J., Justice, R. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.1013 · Cited by 10 · see citing works
A Weekly Schedule of Epirubicin in Pretreated Advanced Breast Cancer
Barni, S., Archili, C., Lissoni, P., et al. (1993) · Tumori Journal · doi:10.1177/030089169307900110 · Cited by 9 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P. G., Manova-Todorova, K., Leversha, M., Hogg, N., Seshan, V. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.042 · Cited by 1,085 · see citing works
Self-citation
- Authors
- Morris, P. G., McArthur, H. L., & Hudis, C. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2009-04
- Volume
- 10
- Issue
- 6
- Pages
- 967-981
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2010663401
- Cited by
- 59
- References
- 96
- Citations by year
- 2026: 1 · 2025: 2 · 2023: 1 · 2022: 2 · 2020: 5 · 2019: 7 · 2018: 4 · 2017: 2 · 2016: 4 · 2015: 6 · 2014: 3 · 2013: 5 · 2012: 7
- FWCI
- 0.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- metastatic breast cancer, cytotoxic chemotherapy, chemotherapy schedule, targeted therapy, trastuzumab, lapatinib, bevacizumab, combination chemotherapy, tumor biology
- MeSH terms
- Bevacizumab, Trastuzumab, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Clinical Trials as Topic, Female, Humans, Survival Rate, Drug Delivery Systems, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
